Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.8%
Tue, 29 Oct 13:30

Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.8%Image source: bluebay2014/www.istockphoto.com

Glenmark Pharma share price has plunged 3% and is presently trading at Rs 1,661.0.

Meanwhile, the BSE HEALTHCARE index is at 43,061.3 (down 0.8%).

Among the top losers in the BSE HEALTHCARE index today are Dr. Reddys (down 3.4%) and POLY MEDICURE (down 3.0%).

CAPLIN POINT (up 3.6%) and MAX HEALTHCARE INSTITUTE (up 2.2%) are among the top gainers today.

Over the last one year, Glenmark Pharma has moved up from Rs 751.5 to Rs 1,661.0, registering a gain of Rs 909.5 (up 121.0%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,318.2 to 43,061.3, registering a gain of 57.6% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 224.6%), Glenmark Pharma (up 121.0%) and SUVEN PHARMACEUTICALS (up 118.8%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,870.7 (down 0.2%).

The top losers among the BSE Sensex today are Tata Motors (down 4.6%) and Indusind Bank (down 2.6%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.

In the meantime, NSE Nifty is at 24,292.5 (down 0.2%). Tata Motors and Dr. Reddys are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,049.1 to 79,870.7, registering a gain of 15,821.6 points (up 24.7%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.

For the year ended March 2024, Glenmark Pharma reported 1944.2% decrease in net profit to Rs -18,309 million compared to net loss of Rs 896 million during FY23. Revenue of the company grew 2.0% to Rs 118,131 million during FY24.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -30.7.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.8%". Click here!